BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30604027)

  • 1. Relationship between changes in metabolic syndrome constituent components over 12 months of treatment and cognitive performance in first-episode schizophrenia.
    Luckhoff HK; Kilian S; Olivier MR; Phahladira L; Scheffler F; du Plessis S; Chiliza B; Asmal L; Emsley R
    Metab Brain Dis; 2019 Apr; 34(2):469-476. PubMed ID: 30604027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive performance during the first year of treatment in first-episode schizophrenia: a case-control study.
    Olivier MR; Killian S; Chiliza B; Asmal L; Schoeman R; Oosthuizen PP; Kidd M; Emsley R
    Psychol Med; 2015 Oct; 45(13):2873-83. PubMed ID: 25998030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive functioning in first-episode schizophrenia: MATRICS Consensus Cognitive Battery (MCCB) Profile of Impairment.
    McCleery A; Ventura J; Kern RS; Subotnik KL; Gretchen-Doorly D; Green MF; Hellemann GS; Nuechterlein KH
    Schizophr Res; 2014 Aug; 157(1-3):33-9. PubMed ID: 24888526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12 months.
    Luckhoff H; Phahladira L; Scheffler F; Asmal L; du Plessis S; Chiliza B; Kilian S; Emsley R
    Schizophr Res; 2019 Apr; 206():171-176. PubMed ID: 30503765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders.
    Trampush JW; Lencz T; DeRosse P; John M; Gallego JA; Petrides G; Hassoun Y; Zhang JP; Addington J; Kellner CH; Tohen M; Burdick KE; Goldberg TE; Kane JM; Robinson DG; Malhotra AK
    Schizophr Bull; 2015 Nov; 41(6):1237-47. PubMed ID: 26409223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurological soft signs in first-episode schizophrenia: State- and trait-related relationships to psychopathology, cognition and antipsychotic medication effects.
    Emsley R; Chiliza B; Asmal L; Kilian S; Riaan Olivier M; Phahladira L; Ojagbemi A; Scheffler F; Carr J; Kidd M; Dazzan P
    Schizophr Res; 2017 Oct; 188():144-150. PubMed ID: 28130002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of cannabis use on body mass, fasting glucose and lipids during the first 12 months of treatment in schizophrenia spectrum disorders.
    Scheffler F; Kilian S; Chiliza B; Asmal L; Phahladira L; du Plessis S; Kidd M; Murray RM; Di Forti M; Seedat S; Emsley R
    Schizophr Res; 2018 Sep; 199():90-95. PubMed ID: 29519756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
    Keefe RS; Fox KH; Harvey PD; Cucchiaro J; Siu C; Loebel A
    Schizophr Res; 2011 Feb; 125(2-3):161-8. PubMed ID: 21075600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG
    Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive and clinical predictors of functional capacity in patients with first episode schizophrenia.
    Vesterager L; Christensen TØ; Olsen BB; Krarup G; Melau M; Forchhammer HB; Nordentoft M
    Schizophr Res; 2012 Nov; 141(2-3):251-6. PubMed ID: 23017825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia.
    Bishop JR; Reilly JL; Harris MS; Patel SR; Kittles R; Badner JA; Prasad KM; Nimgaonkar VL; Keshavan MS; Sweeney JA
    Psychopharmacology (Berl); 2015 Jan; 232(1):145-54. PubMed ID: 25096017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
    Harvey PD; Ogasa M; Cucchiaro J; Loebel A; Keefe RS
    Schizophr Res; 2011 Apr; 127(1-3):188-94. PubMed ID: 21277745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
    Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
    Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impacts of duration of untreated psychosis on cognition and negative symptoms in first-episode schizophrenia: a 3-year prospective follow-up study.
    Chang WC; Hui CL; Tang JY; Wong GH; Chan SK; Lee EH; Chen EY
    Psychol Med; 2013 Sep; 43(9):1883-93. PubMed ID: 23217676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders.
    Potvin S; Aubin G; Stip E
    Eur Arch Psychiatry Clin Neurosci; 2015 Mar; 265(2):147-54. PubMed ID: 24925606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic.
    Kitajima R; Miyamoto S; Tenjin T; Ojima K; Ogino S; Miyake N; Fujiwara K; Funamoto Y; Arai J; Tsukahara S; Ito Y; Tadokoro M; Anai K; Kaneda Y; Yamaguchi N
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):300-6. PubMed ID: 22122880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive functioning in the early course of first-episode schizophrenia spectrum disorders: timing and patterns.
    González-Blanch C; Alvarez-Jiménez M; Rodríguez-Sánchez JM; Pérez-Iglesias R; Vázquez-Barquero JL; Crespo-Facorro B
    Eur Arch Psychiatry Clin Neurosci; 2006 Sep; 256(6):364-71. PubMed ID: 16788772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive effects of six months of treatment with quetiapine in antipsychotic-naïve first-episode schizophrenia.
    Andersen R; Fagerlund B; Rasmussen H; Ebdrup BH; Aggernaes B; Gade A; Oranje B; Glenthoj B
    Psychiatry Res; 2011 May; 187(1-2):49-54. PubMed ID: 21075453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.